Cannabics Pharmaceuticals Inc. Engages with the Technion Institute for the Screening of Potential Anticancer Cannabinoid Compounds
BETHESDA, Md., Apr. 6, 2015 /PRNewswire/ --Cannabics Pharmaceuticals Inc. (OTCQB:CNBX) announced today that it has executed a Research Agreement with the Israel Institute of Technology (Technion) in Israel, for the screening of potential Anticancer Cannabinoid compounds.
Under the terms of the agreement, Cannabics Pharmaceuticals will collaborate with a researcher from the Biology Department of the Technion to develop a diagnostic system that screens the anti-cancer properties of cannabis-based active ingredients. This system would be harnessed to explore different types of cancer cells treated with a multitude of cannabinoid combinations.
Dr. Eyal Ballan, Chief scientist of Cannabics Pharmaceuticals, stated, "Cannabinoid based anticancer medicine could be a potent therapy without the side effects related to chemotherapy. We are excited to have the opportunity to collaborate with such highly experienced and motivated scientists."
The head of the laboratory of Cancer Biology and Cannabinoid Research was quoted as saying "There is a large body of scientific data which indicates that Cannabinoids specifically inhibit Cancer cell growth and promote Cancer cell death. In addition to active Cannabinoids, Cannabis plants also contain a multitude of other therapeutic agents, such as terpenoids and flavonoids that are usually present in small quantities, but can have beneficial therapeutic effects, especially as synergistic compounds to cannabinoids."
About Cannabics Pharmaceuticals, Inc.
Cannabics Pharmaceuticals, Inc. is an emerging drug company focused on the development and commercialization of advanced drugs, therapies, food supplements and administration routes based on the wide range of active ingredients found in diverse and unique strains of the Cannabis plant. Cannabics' current flagship product is Cannabics SR an IP pending medical cannabis capsule designed specifically for cancer patients as a palliative care treatment. Cannabics is now preparing to launch its line of SR products in eligible states of the US and EU markets under existing medical cannabis regulatory pathways, while simultaneously launching a formal clinical study in order to establish the unique medical benefits of its SR capsules.
For more information, visit http://www.Cannabics.com
About the Technion
Technion – Israel Institute of Technology is consistently ranked amongst the world's top science and Technology Research Universities. The Faculty of Biology is comprised of 23 independent research groups, focusing on a variety of aspects of Cellular, Molecular and Developmental Biology. The faculty has extensive collaborations with the pharmaceutical and biotechnology industries.
DISCLAIMER:
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on January 20th, 2015. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
For Further Information, please contact:
Cannabics Pharmaceuticals, Inc.
Itamar Borochov, CEO
+1-877-424-2429
[email protected]
SOURCE Cannabics Pharmaceuticals Inc.
Share this article